Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1531 to 1545 of 1766 results for patient safety

  1. Laparoscopic nephrolithotomy and pyelolithotomy (HTG137)

    Evidence-based recommendations on laparoscopic nephrolithotomy and pyelolithotomy. This involves inserting a tube through small cuts in the abdomen (keyhole surgery) to remove the kidney stones..

    HealthTech guidance
    Published
    28 March 2007
    View recommendations

    Sections for HTG137

  2. Further research into implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis should include comparative studies against existing forms of management. Studies should record patient selection, functional outcomes, quality of life and complications. They should also report the nature and timing of any further surgery on the knee and the effect of removing the device. A minimum follow-up period of 2–3 years is needed. NICE may update the guidance on publication of further evidence.

    comparative studies against existing forms of management. Studies should record patient selection, functional outcomes, quality of life...

    Research recommendation
    Published
    9 June 2015

  3. NICE encourages further research into ultrasound-enhanced, catheter-directedthrombolysis for pulmonary embolism. Ideally this should include comparative studies against catheter-directed thrombolysis alone. Patient selection should be  documented. The dose of thrombolytic agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the success of thrombolysis (complete, partial or failed) and long-term sequelae. NICE may update the guidance on publication of further evidence.

    include comparative studies against catheter-directed thrombolysis alone. Patient selection should be documented. The dose of...

    Research recommendation
    Published
    6 October 2015

  4. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis.

    Highly specialised technologies guidance
    Published
    22 May 2019
    View recommendations

    Sections for HST9

  5. NICE encourages further research comparing ultrasound-enhanced, catheter-directed thrombolysis for deep vein thrombosis against catheter-directed thrombolysis alone. Patient selection should be documented, including the duration and extent of thrombosis. The dose of thrombolytic agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the success of thrombolysis (complete, partial or failed) and long-term sequelae. NICE may update the guidance on publication of further evidence.

    for deep vein thrombosis against catheter-directed thrombolysis alone. Patient selection should be documented, including the duration...

    Research recommendation
    Published
    5 October 2015

  6. Evidence on the efficacy of bioresorbable stent implantation to treat coronary artery disease is inadequate. Evidence on its safety has shown an increased risk of serious complications in the longer term. This includes an increased risk of myocardial infarction and death with some types of bioresorbable stents. Therefore, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    implantation to treat coronary artery disease is inadequate. Evidence on its safety has shown an increased risk of serious complications...

    Research recommendation
    Published
    7 September 2022

  7. Further research in people who could have conventional cardiac pacemaker implantation should report the patient selection criteria and compare leadless pacemakers with conventional pacemakers. Follow-up should be for at least 5 years and outcomes should include adverse events, symptom relief, quality of life and device durability in the long-term.

    could have conventional cardiac pacemaker implantation should report the patient selection criteria and compare leadless pacemakers with...

    Research recommendation
    Published
    12 December 2018

  8. MolecuLight i:X for wound imaging (MIB212)

    NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .

    Medtech innovation briefing
    Published
    18 June 2020

  9. NICE encourages further research into preoperative high dose rate brachytherapy for rectal cancer. Trials should be designed to provide clear data on the efficacy of this procedure, whether or not other adjunctive treatments are used. Research should document adjunctive treatments and details of patient selection. Outcomes should include local recurrence, survival, disease-free survival and quality of life. NICE may update the guidance on publication of further evidence.

    are used. Research should document adjunctive treatments and details of patient selection. Outcomes should include local recurrence,...

    Research recommendation
    Published
    12 October 2015

  10. Transition between inpatient mental health settings and community or care home settings (NG53)

    This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.

    NICE guideline
    Published
    30 August 2016
    View recommendations

    Sections for NG53

  11. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST25

  12. NICE encourages further research on transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. Studies should describe whether the procedure is used for treatment or prevention, and whether it is used for cluster headache or migraine. Clinicians should clearly document details of patient selection and the treatment regimen. Outcome measures should include changes in the number and severity of cluster headache or migraine episodes, medication use, quality of life in the short and long term, side effects, acceptability, and device  durability. NICE may update this guidance on publication of further evidence.

    cluster headache or migraine. Clinicians should clearly document details of patient selection and the treatment regimen. Outcome...

    Research recommendation
    Published
    6 April 2016

  13. Values of skin prick testing and specific IgE antibody testing and their predictive value:- Can skin prick testing and specific IgE antibody testing cut-off points be established to diagnose IgE-mediated food allergy in children and young people, and to predict the severity of reaction?

    allergies. Food challenges are cumbersome and time-consuming and there are some safety risks involved. The availability of skin prick...

    Research recommendation
    Published
    9 June 2015

  14. Bindex for investigating suspected osteoporosis (MIB106)

    NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .

    Medtech innovation briefing
    Published
    31 May 2017

  15. Spondyloarthritis in over 16s: diagnosis and management (NG65)

    This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

    NICE guideline
    Last updated
    2 June 2017
    View recommendations

    Sections for NG65